ReviewAAPS PharmSciTech2026
Chitosan-Based Nose-to-Brain Drug Delivery for Management of Neurological Disorders: Intrinsic Neuroprotective Action and Carrier Capabilities.
Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological disorders represent a major global health burden, primarily due to the limited ability of therapeutic agents to cross the blood-brain barrier (BBB). Nose-to-brain (NTB) delivery has emerged as a promising non-invasive strategy to bypass the BBB and directly target the central nervous system (CNS). Among various polymers, chitosan has gained significant attention owing to its favourable physicochemical properties, biocompatibility, biodegradability, mucoadhesive nature, and ability to transiently open tight junctions of the nasal epithelium. This review comprehensively discusses the potential of chitosan-based systems for NTB delivery in the management of neurological disorders. The article outlines the physicochemical properties and biomedical applications of chitosan, followed by a detailed discussion of nasal anatomy and transport pathways involved in NTB drug delivery. The pharmacological aspects of chitosan in neurological disorders are highlighted, including its anti-oxidative, anti-neuroinflammatory, anti-apoptotic, anti-excitotoxic effects, suppression of β-amyloid accumulation, and acetylcholinesterase inhibitory activity. Various formulation approaches are critically reviewed, including chitosan-based nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, liposomes, microparticles, microspheres, and in situ gels designed for intranasal administration. Furthermore, surface-modified chitosan systems aimed at enhancing brain targeting are discussed, such as PEGylation, ligand-conjugated chitosan (transferrin and lactoferrin), cell-penetrating peptide functionalization, thiolated chitosan, and pH-sensitive derivatives including carboxymethyl and N-trimethyl chitosan. Comparative tables summarize formulation strategies, neurological indications, biological models, key outcomes, and reported findings. Overall, this review highlights the significant potential of chitosan and its surface-engineered derivatives as versatile carriers for NTB delivery in neurological disorders.
Indexed as
Identifiers
42816727What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.